|
KMID : 1145520190050010026
|
|
Journal of Radiopharmaceuticals and Molecular Probes
2019 Volume.5 No. 1 p.26 ~ p.35
|
|
|
188Re Labeled liver therapeutic drugs for hepatic carcinoma (HCC)
|
|
Seelam Sudhakara Reddy
Banka Vinay Kumar
Lee Yun-Sang
Jeong Jae-Min
|
|
|
Abstract
|
|
|
|
188Re is one of the most readily available generator derived and useful radionuclides for therapy emitting β?particles (2.12 MeV, 71.1% and 1.965 MeV, 25.6%) and imageable gammas (155 keV, 15.1%). The 188W/188Re generator is an ideal source for the long term (4-6 months) continuous availability of no carrier added (NCA) 188Re suitable for the preparation of radiopharmaceuticals for radionuclide therapy. Rhenium-188 has been used for the preparation of therapeutic radiopharmaceuticals for the management of diseases such as bone metastasis, rheumatoid arthritis and primary cancers. Several early phase clinical studies using radiopharmaceuticals based on 188Re -labeled phosphonates, antibodies, peptides, lipiodol and particulates have been reported. In this review, we addressed the current development status of 188Re radiopharmaceuticals for liver cancer therapy and their applications.
|
|
|
KEYWORD
|
|
|
188Re, Rhenium, Hepatic Carcinoma, Lipiodol, N2S2, HDD, TDD, HTDD
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|